Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colorectal Cancer, The ERASur Study

Purpose

This phase III trial compares total ablative therapy and usual systemic therapy to usual systemic therapy alone in treating patients with colorectal cancer that has spread to up to 4 body sites (limited metastatic). The usual approach for patients who are not participating in a study is treatment with intravenous (IV) (through a vein) and/or oral medications (systemic therapy) to help stop the cancer sites from getting larger and the spread of the cancer to additional body sites. Ablative means that the intention of the local treatment is to eliminate the cancer at that metastatic site. The ablative local therapy will consist of very focused, intensive radiotherapy called stereotactic ablative radiotherapy (SABR) with or without surgical resection and/or microwave ablation, which is a procedure where a needle is temporarily inserted in the tumor and heat is used to destroy the cancer cells. SABR, surgical resection, and microwave ablation have been tested for safety, but it is not scientifically proven that the addition of these treatments are beneficial for your stage of cancer. The addition of ablative local therapy to all known metastatic sites to the usual approach of systemic therapy could shrink or remove the tumor(s) or prevent the tumor(s) from returning.

Conditions

  • Metastatic Colorectal Adenocarcinoma
  • Stage IV Colorectal Cancer AJCC v8

Eligibility

Eligible Ages
Over 18 Years
Eligible Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • PRE-REGISTRATION (STEP 0): Histologically-confirmed metastatic colorectal adenocarcinoma - PRE-REGISTRATION (STEP 0): No known microsatellite instable (MSI) tumor - PRE-REGISTRATION (STEP 0): No known BRAF V600E mutation - PRE-REGISTRATION (STEP 0): Patients with treated brain metastases are eligible if follow-up brain imaging after central nervous system (CNS)-directed therapy shows no evidence of progression. No known peritoneal and/or omental metastases. If radiologic studies suggest the presence of peritoneal disease, a diagnostic laparoscopy is recommended to verify the absence of peritoneal implants - PRE-REGISTRATION (STEP 0): Primary tumor is already resected OR primary tumor is surgically amenable to resection, as determined by consultation and documentation with surgeon or documentation of discussion in the institutional multi-disciplinary tumor board where a surgeon confirms resectability. Patients with unresectable primary tumors are not eligible - PRE-REGISTRATION (STEP 0): Four (4) or fewer apparent sites of metastatic disease based on review by local medical team of baseline radiographic imaging obtained prior to initiation of systemic therapy. - Sites of metastatic disease must be radiographically evident, but pathologic confirmation is not required. - Liver-only metastatic disease is NOT permitted. For patients with liver metastases, there must be at least one other site of metastasis in addition to the liver to be eligible for this study. - Metastatic lesions must be amenable to any combination of surgical resection, microwave ablation, and/or stereotactic ablative body radiation therapy (SABR). SABR is required for at least one lesion. Therefore, the patient must be seen by a radiation oncologist in consultation to verify eligibility. - Single sites include: - Each hemiliver (right and left), each lobe of the lungs, each adrenal gland, lymph nodes amenable to a single resection or treatment in a single SABR field, bone metastases amenable to treatment in a single SABR field - PRE-REGISTRATION (STEP 0): Patients must have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1 - PRE-REGISTRATION (STEP 0): A maximum of 16 weeks (4 months) of systemic therapy may be administered prior to pre-registration - REGISTRATION (STEP 1): Patients must have no overt evidence of disease progression during systemic therapy prior to registration - REGISTRATION (STEP 1): Not eligible for hepatic artery infusion pump (HAIP) therapy or benefit of HAIP therapy is undefined - REGISTRATION (STEP 1): Patients must have measurable disease per RECIST v1.1 - REGISTRATION (STEP 1): Patients must be receiving (or have received) first-line systemic therapy for metastatic disease for a minimum of 16 weeks (4 months) and a maximum of 24 weeks (6 months) - REGISTRATION (STEP 1): Prior definitive therapy, including adjuvant chemotherapy, must have been completed at least 12 months prior to diagnosis of metastatic disease - REGISTRATION (STEP 1): Not pregnant and not nursing, because this study involves an agent or treatment that has known genotoxic, mutagenic, and teratogenic effects. * Therefore, for women of childbearing potential only, a negative pregnancy test done =< 14 days prior to registration is required - REGISTRATION (STEP 1): Age >= 18 years - REGISTRATION (STEP 1): Eastern Cooperative Oncology Group (ECOG) performance status: 0-2 - REGISTRATION (STEP 1): Absolute neutrophil count (ANC) >= 1,500/mm^3 - REGISTRATION (STEP 1): Platelet count >= 50,000/mm^3 - REGISTRATION (STEP 1): Creatinine =< 1.5 x upper limit of normal (ULN) OR calculated (calc.) creatinine clearance >= 30 mL/min * Calculated using the Cockcroft-Gault equation - REGISTRATION (STEP 1): Total bilirubin =< 1.5 x ULN - REGISTRATION (STEP 1): Aspartate aminotransferase (AST)(serum glutamic-oxaloacetic transaminase [SGOT]) / alanine aminotransferase (ALT)(serum glutamate pyruvate transaminase [SGPT]) =< 3.0 x ULN * In the event of metastatic liver disease, =< 5 x ULN - REGISTRATION (STEP 1): Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial. Note: HIV testing is not required for eligibility - REGISTRATION (STEP 1): No other planned concurrent investigational agents while on study

Exclusion Criteria

  • N/A

Study Design

Phase
Phase 3
Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel Assignment
Primary Purpose
Treatment
Masking
None (Open Label)

Arm Groups

ArmDescriptionAssigned Intervention
Experimental
Arm 1 (TAT, SOC chemotherapy 		Patients undergo TAT on study, consisting of SABR with or without surgical resection and/or microwave ablation. Patients also receive SOC chemotherapy on study. Patients also undergo CT or MRI or PET/CT scans throughout the trial.
  • Procedure: Stereotactic Ablative Radiotherapy
    Undergo SABR
    Other names:
    • SABER
    • SABR/SBRT
  • Procedure: Resection
    undergo surgical resection
    Other names:
    • Surgical resection
  • Procedure: Microwave Ablation
    undergo microwave ablation
    Other names:
    • Ablation
  • Drug: Chemotherapy
    Receive SOC chemotherapy
    Other names:
    • Chemo
  • Procedure: Computed Tomography
    Undergo CT scan
    Other names:
    • CAT
    • CAT Scan
    • Computed Axial Tomography
    • CT Scan
  • Procedure: Magnetic Resonance Imaging
    Undergo MRI
    Other names:
    • MRI
  • Procedure: Positron Emission Tomography
    Undergo PET scan
    Other names:
    • Medical Imaging, Positron Emission Tomography
    • PET
    • PET Scan
Active Comparator
Arm 2 (SOC chemotherapy) 		Patients receive SOC chemotherapy on study. Patients also undergo Patients also undergo CT or MRI or PET/CT scans throughout the trial.
  • Drug: Chemotherapy
    Receive SOC chemotherapy
    Other names:
    • Chemo
  • Procedure: Computed Tomography
    Undergo CT scan
    Other names:
    • CAT
    • CAT Scan
    • Computed Axial Tomography
    • CT Scan
  • Procedure: Magnetic Resonance Imaging
    Undergo MRI
    Other names:
    • MRI
  • Procedure: Positron Emission Tomography
    Undergo PET scan
    Other names:
    • Medical Imaging, Positron Emission Tomography
    • PET
    • PET Scan

Recruiting Locations

Kingman Regional Medical Center
Kingman, Arizona 86401
Contact:
Site Public Contact
702-384-0013
research@sncrf.org

Mayo Clinic Hospital in Arizona
Phoenix, Arizona 85054
Contact:
Site Public Contact
855-776-0015

Tower Cancer Research Foundation
Beverly Hills, California 90211
Contact:
Site Public Contact
towercancerresearch@toweroncology.com

UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care
Irvine, California 92612
Contact:
Site Public Contact
877-827-8839
ucstudy@uci.edu

Cedars Sinai Medical Center
Los Angeles, California 90048
Contact:
Site Public Contact
310-423-8965

UC Irvine Health/Chao Family Comprehensive Cancer Center
Orange, California 92868
Contact:
Site Public Contact
877-827-8839
ucstudy@uci.edu

Beebe Medical Center
Lewes, Delaware 19958
Contact:
Site Public Contact
302-291-6730
research@beebehealthcare.org

Beebe South Coastal Health Campus
Millville, Delaware 19967
Contact:
Site Public Contact
302-291-6730
research@beebehealthcare.org

Helen F Graham Cancer Center
Newark, Delaware 19713
Contact:
Site Public Contact
302-623-4450
lbarone@christianacare.org

Medical Oncology Hematology Consultants PA
Newark, Delaware 19713
Contact:
Site Public Contact
302-623-4450
lbarone@christianacare.org

Christiana Care Health System-Christiana Hospital
Newark, Delaware 19718
Contact:
Site Public Contact
302-623-4450
lbarone@christianacare.org

Beebe Health Campus
Rehoboth Beach, Delaware 19971
Contact:
Site Public Contact
302-291-6730
research@beebehealthcare.org

Christiana Care Health System-Wilmington Hospital
Wilmington, Delaware 19801
Contact:
Site Public Contact
302-623-4450
lbarone@christianacare.org

George Washington University Medical Center
Washington D.C., District of Columbia 20037
Contact:
Site Public Contact
202-741-2210

UM Sylvester Comprehensive Cancer Center at Coral Gables
Coral Gables, Florida 33146
Contact:
Site Public Contact
305-243-2647

UM Sylvester Comprehensive Cancer Center at Coral Springs
Coral Springs, Florida 33065
Contact:
Site Public Contact
305-243-2647

UM Sylvester Comprehensive Cancer Center at Deerfield Beach
Deerfield Beach, Florida 33442
Contact:
Site Public Contact
305-243-2647

UM Sylvester Comprehensive Cancer Center at Doral
Doral, Florida 33166
Contact:
Site Public Contact
kginnity@med.miami.edu

UF Health Cancer Institute - Gainesville
Gainesville, Florida 32610
Contact:
Site Public Contact
352-273-8010

UM Sylvester Comprehensive Cancer Center at Hollywood
Hollywood, Florida 33021
Contact:
Site Public Contact
305-243-2647

University of Miami Miller School of Medicine-Sylvester Cancer Center
Miami, Florida 33136
Contact:
Site Public Contact
305-243-2647

UM Sylvester Comprehensive Cancer Center at Kendall
Miami, Florida 33176
Contact:
Site Public Contact
305-243-2647

UM Sylvester Comprehensive Cancer Center at Plantation
Plantation, Florida 33324
Contact:
Site Public Contact
305-243-2647

Grady Health System
Atlanta, Georgia 30303
Contact:
Site Public Contact
404-778-1868

Emory Proton Therapy Center
Atlanta, Georgia 30308
Contact:
Site Public Contact
404-251-2854
allyson.anderson@emory.edu

Emory University Hospital Midtown
Atlanta, Georgia 30308
Contact:
Site Public Contact
888-946-7447

Emory University Hospital/Winship Cancer Institute
Atlanta, Georgia 30322
Contact:
Site Public Contact
404-778-1868

Emory Saint Joseph's Hospital
Atlanta, Georgia 30342
Contact:
Site Public Contact
404-851-7115

Saint Luke's Cancer Institute - Boise
Boise, Idaho 83712
Contact:
Site Public Contact
208-381-2774
eslinget@slhs.org

Saint Luke's Cancer Institute - Fruitland
Fruitland, Idaho 83619
Contact:
Site Public Contact
208-381-2774
eslinget@slhs.org

Saint Luke's Cancer Institute - Meridian
Meridian, Idaho 83642
Contact:
Site Public Contact
208-381-2774
eslinget@slhs.org

Saint Luke's Cancer Institute - Nampa
Nampa, Idaho 83687
Contact:
Site Public Contact
208-381-2774
eslinget@slhs.org

Saint Luke's Cancer Institute - Twin Falls
Twin Falls, Idaho 83301
Contact:
Site Public Contact
208-381-2774
eslinget@slhs.org

University of Illinois
Chicago, Illinois 60612
Contact:
Site Public Contact
312-355-3046

UI Health Care Mission Cancer and Blood - Ankeny Clinic
Ankeny, Iowa 50023
Contact:
Site Public Contact
515-241-3305

University of Iowa Healthcare Cancer Services Quad Cities
Bettendorf, Iowa 52722
Contact:
Site Public Contact
563-355-7733
katherine-daprile@uiowa.edu

Mercy Cancer Center-West Lakes
Clive, Iowa 50325
Contact:
Site Public Contact
515-241-3305

UI Health Care Mission Cancer and Blood - West Des Moines Clinic
Clive, Iowa 50325
Contact:
Site Public Contact
515-241-3305

Greater Regional Medical Center
Creston, Iowa 50801
Contact:
Site Public Contact
515-241-3305

Iowa Methodist Medical Center
Des Moines, Iowa 50309
Contact:
Site Public Contact
515-241-6727

UI Health Care Mission Cancer and Blood - Des Moines Clinic
Des Moines, Iowa 50309
Contact:
Site Public Contact
515-241-3305

Mercy Medical Center - Des Moines
Des Moines, Iowa 50314
Contact:
Site Public Contact
515-241-3305

UI Health Care Mission Cancer and Blood - Laurel Clinic
Des Moines, Iowa 50314
Contact:
Site Public Contact
515-241-3305

University of Iowa/Holden Comprehensive Cancer Center
Iowa City, Iowa 52242
Contact:
Site Public Contact
800-237-1225

UI Health Care Mission Cancer and Blood - Waukee Clinic
Waukee, Iowa 50263
Contact:
Site Public Contact
515-241-3305

Mercy Medical Center-West Lakes
West Des Moines, Iowa 50266
Contact:
Site Public Contact
515-241-3305

Baptist Health Louisville
Louisville, Kentucky 40207
Contact:
Site Public Contact
502-897-8592
Cbcresearch@bhsi.com

University Medical Center New Orleans
New Orleans, Louisiana 70112
Contact:
Site Public Contact
504-210-3539
emede1@lsuhsc.edu

Boston Medical Center
Boston, Massachusetts 02118
Contact:
Site Public Contact
617-638-8265

Trinity Health Saint Joseph Mercy Hospital Ann Arbor
Ann Arbor, Michigan 48106
Contact:
Site Public Contact
734-712-7251
MCRCwebsitecontactform@stjoeshealth.org

Trinity Health IHA Medical Group Hematology Oncology - Brighton
Brighton, Michigan 48114
Contact:
Site Public Contact
734-712-7251
MCRCwebsitecontactform@stjoeshealth.org

Trinity Health Medical Center - Brighton
Brighton, Michigan 48114
Contact:
Site Public Contact
734-712-7251
MCRCwebsitecontactform@stjoeshealth.org

Trinity Health IHA Medical Group Hematology Oncology - Canton
Canton, Michigan 48188
Contact:
Site Public Contact
734-712-7251
MCRCwebsitecontactform@stjoeshealth.org

Trinity Health Medical Center - Canton
Canton, Michigan 48188
Contact:
Site Public Contact
734-712-7251
MCRCwebsitecontactform@stjoeshealth.org

Chelsea Hospital
Chelsea, Michigan 48118
Contact:
Site Public Contact
734-712-7251
MCRCwebsitecontactform@stjoeshealth.org

Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital
Chelsea, Michigan 48118
Contact:
Site Public Contact
734-712-7251
MCRCwebsitecontactform@stjoeshealth.org

Corewell Health Dearborn Hospital
Dearborn, Michigan 48124
Contact:
Site Public Contact
248-551-7695

Henry Ford Hospital
Detroit, Michigan 48202
Contact:
Site Public Contact
313-916-3721
CTOResearch@hfhs.org

Corewell Health Farmington Hills Hospital
Farmington Hills, Michigan 48336
Contact:
Site Public Contact
248-551-7695

Genesys Hurley Cancer Institute
Flint, Michigan 48503
Contact:
Site Public Contact
810-762-8038
wstrong@ghci.org

Hurley Medical Center
Flint, Michigan 48503
Contact:
Site Public Contact
810-762-8038
wstrong@ghci.org

University of Michigan Health - Sparrow Lansing
Lansing, Michigan 48912
Contact:
Site Public Contact
517-364-3712
harsha.trivedi@umhsparrow.org

Trinity Health Saint Mary Mercy Livonia Hospital
Livonia, Michigan 48154
Contact:
Site Public Contact
734-712-7251
MCRCwebsitecontactform@stjoeshealth.org

Henry Ford Health Providence Novi Hospital
Novi, Michigan 48374
Contact:
Site Public Contact
248-849-5332
kfife3@hfhs.org

Corewell Health William Beaumont University Hospital
Royal Oak, Michigan 48073
Contact:
Site Public Contact
248-551-7695

Henry Ford Health Providence Southfield Hospital
Southfield, Michigan 48075
Contact:
Site Public Contact
248-849-5332
kfife3@hfhs.org

Corewell Health Beaumont Troy Hospital
Troy, Michigan 48085
Contact:
Site Public Contact
248-551-7695

Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus
Ypsilanti, Michigan 48197
Contact:
Site Public Contact
734-712-7251
MCRCwebsitecontactform@stjoeshealth.org

Sanford Joe Lueken Cancer Center
Bemidji, Minnesota 56601
Contact:
Site Public Contact
218-333-5000
OncologyClinicalTrialsFargo@sanfordhealth.org

Regions Hospital
Saint Paul, Minnesota 55101
Contact:
Site Public Contact
952-993-1517
mmcorc@healthpartners.com

Baptist Memorial Hospital and Cancer Center-Golden Triangle
Columbus, Mississippi 39705
Contact:
Site Public Contact
901-226-1366
BCCclintrials@bmhcc.org

Baptist Cancer Center-Grenada
Grenada, Mississippi 38901
Contact:
Site Public Contact
901-226-1366
BCCclintrials@bmhcc.org

Baptist Memorial Hospital and Cancer Center-Union County
New Albany, Mississippi 38652
Contact:
Site Public Contact
901-226-1366
BCCclintrials@bmhcc.org

Baptist Memorial Hospital and Cancer Center-Oxford
Oxford, Mississippi 38655
Contact:
Site Public Contact
901-226-1366
BCCclintrials@bmhcc.org

Baptist Memorial Hospital and Cancer Center-Desoto
Southhaven, Mississippi 38671
Contact:
Site Public Contact
901-226-1366
BCCclintrials@bmhcc.org

MU Health - University Hospital/Ellis Fischel Cancer Center
Columbia, Missouri 65212
Contact:
Site Public Contact
573-882-7440

Parkland Health Center - Farmington
Farmington, Missouri 63640
Contact:
Site Public Contact
314-996-5569

Heartland Regional Medical Center
Saint Joseph, Missouri 64506
Contact:
Site Public Contact
816-271-7937
Trisha.England2@mymlc.com

Sainte Genevieve County Memorial Hospital
Sainte Genevieve, Missouri 63670
Contact:
Site Public Contact
314-996-5569

Mercy Hospital Springfield
Springfield, Missouri 65804
Contact:
Site Public Contact
417-269-4520

Mercy Hospital South
St Louis, Missouri 63128
Contact:
Site Public Contact
314-525-6042
Danielle.Werle@mercy.net

Missouri Baptist Medical Center
St Louis, Missouri 63131
Contact:
Site Public Contact
314-996-5569

Mercy Hospital Saint Louis
St Louis, Missouri 63141
Contact:
Site Public Contact
314-251-7066

Missouri Baptist Sullivan Hospital
Sullivan, Missouri 63080
Contact:
Site Public Contact
314-996-5569

BJC Outpatient Center at Sunset Hills
Sunset Hills, Missouri 63127
Contact:
Site Public Contact
314-996-5569

Billings Clinic Cancer Center
Billings, Montana 59101
Contact:
Site Public Contact
800-996-2663
research@billingsclinic.org

Benefis Sletten Cancer Institute
Great Falls, Montana 59405
Contact:
Site Public Contact
406-969-6060
mccinfo@mtcancer.org

Nebraska Medicine-Bellevue
Bellevue, Nebraska 68123
Contact:
Site Public Contact
402-559-6941
unmcrsa@unmc.edu

Nebraska Medicine-Village Pointe
Omaha, Nebraska 68118
Contact:
Site Public Contact
402-559-5600

University of Nebraska Medical Center
Omaha, Nebraska 68198
Contact:
Site Public Contact
402-559-6941
unmcrsa@unmc.edu

Renown Regional Medical Center
Reno, Nevada 89502
Contact:
Site Public Contact
702-384-0013
research@sncrf.org

Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center
Lebanon, New Hampshire 03756
Contact:
Site Public Contact
800-639-6918
cancer.research.nurse@dartmouth.edu

Memorial Sloan Kettering Basking Ridge
Basking Ridge, New Jersey 07920
Contact:
Site Public Contact
212-639-7592

Memorial Sloan Kettering Monmouth
Middletown, New Jersey 07748
Contact:
Site Public Contact
212-639-7592

Memorial Sloan Kettering Bergen
Montvale, New Jersey 07645
Contact:
Site Public Contact
212-639-7592

University of New Mexico Cancer Center
Albuquerque, New Mexico 87106
Contact:
Site Public Contact
505-925-0348
HSC-ClinicalTrialInfo@salud.unm.edu

New York-Presbyterian/Brooklyn Methodist Hospital
Brooklyn, New York 11215
Contact:
Site Public Contact
718-780-3677
Adg9003@nyp.org

Memorial Sloan Kettering Commack
Commack, New York 11725
Contact:
Site Public Contact
212-639-7592

The New York Hospital Medical Center of Queens
Flushing, New York 11355
Contact:
Site Public Contact
888-823-5923
ctsucontact@westat.com

Northwell Health Physicians Partners Radiation Medicine at Queens
Forest Hills, New York 11375
Contact:
Site Public Contact
718-520-6620

Northwell Health Cancer Institute at Huntington
Greenlawn, New York 11740
Contact:
Site Public Contact
516-734-8896

Memorial Sloan Kettering Westchester
Harrison, New York 10604
Contact:
Site Public Contact
212-639-7592

Northwell Health/Center for Advanced Medicine
Lake Success, New York 11042
Contact:
Site Public Contact
516-734-8896

Northern Westchester Hospital
Mount Kisco, New York 10549
Contact:
Site Public Contact
914-666-1366
AMellor@northwell.edu

Mount Sinai West
New York, New York 10019
Contact:
Site Public Contact
212-824-7309
CCTO@mssm.edu

Mount Sinai Hospital
New York, New York 10029
Contact:
Site Public Contact
212-824-7309
CCTO@mssm.edu

Manhattan Eye Ear and Throat Hospital
New York, New York 10065
Contact:
Site Public Contact
212-434-4460

Memorial Sloan Kettering Cancer Center
New York, New York 10065
Contact:
Site Public Contact
212-639-7592

NYP/Weill Cornell Medical Center
New York, New York 10065
Contact:
Site Public Contact
212-746-1848

Lenox Hill Hospital
New York, New York 10075
Contact:
Site Public Contact
516-734-8896

Queens Cancer Center
Rego Park, New York 11374
Contact:
Site Public Contact
718-312-3446

Phelps Memorial Hospital Center
Sleepy Hollow, New York 10591
Contact:
Site Public Contact
914-366-1600

Memorial Sloan Kettering Nassau
Uniondale, New York 11553
Contact:
Site Public Contact
212-639-7592

Westchester Medical Center
Valhalla, New York 10595
Contact:
Site Public Contact
888-823-5923
ctsucontact@westat.com

Carolinas Medical Center/Levine Cancer Institute
Charlotte, North Carolina 28203
Contact:
Site Public Contact
800-804-9376

Atrium Health Cabarrus/LCI-Concord
Concord, North Carolina 28025
Contact:
Site Public Contact
800-804-9376

East Carolina University
Greenville, North Carolina 27834
Contact:
Site Public Contact
252-744-1015
eubankss@ecu.edu

Sanford Bismarck Medical Center
Bismarck, North Dakota 58501
Contact:
Site Public Contact
701-323-5760
OncologyClinicalTrialsFargo@sanfordhealth.org

Sanford Broadway Medical Center
Fargo, North Dakota 58122
Contact:
Site Public Contact
701-323-5760
OncologyClinicalTrialsFargo@sanfordhealth.org

Sanford Roger Maris Cancer Center
Fargo, North Dakota 58122
Contact:
Site Public Contact
701-234-6161
OncologyClinicalTrialsFargo@sanfordhealth.org

Miami Valley Hospital South
Centerville, Ohio 45459
Contact:
Site Public Contact
937-528-2900
clinical.trials@daytonncorp.org

Ohio State University Comprehensive Cancer Center
Columbus, Ohio 43210
Contact:
Site Public Contact
800-293-5066
Jamesline@osumc.edu

Miami Valley Hospital
Dayton, Ohio 45409
Contact:
Site Public Contact
937-528-2900
clinical.trials@daytonncorp.org

Premier Blood and Cancer Center
Dayton, Ohio 45409
Contact:
Site Public Contact
937-276-8320

Miami Valley Hospital North
Dayton, Ohio 45415
Contact:
Site Public Contact
937-528-2900
clinical.trials@daytonncorp.org

Atrium Medical Center-Middletown Regional Hospital
Franklin, Ohio 45005-1066
Contact:
Site Public Contact
937-528-2900
clinical.trials@daytonncorp.org

Miami Valley Cancer Care and Infusion
Greenville, Ohio 45331
Contact:
Site Public Contact
937-569-7515

Upper Valley Medical Center
Troy, Ohio 45373
Contact:
Site Public Contact
937-528-2900
clinical.trials@daytonncorp.org

Oregon Health and Science University
Portland, Oregon 97239
Contact:
Site Public Contact
503-494-1080
trials@ohsu.edu

Christiana Care Health System-Concord Health Center
Chadds Ford, Pennsylvania 19317
Contact:
Site Public Contact
302-623-4450
lbarone@christianacare.org

Geisinger Medical Center
Danville, Pennsylvania 17822
Contact:
Site Public Contact
570-271-5251
HemonCCTrials@geisinger.edu

Penn State Milton S Hershey Medical Center
Hershey, Pennsylvania 17033-0850
Contact:
Site Public Contact
717-531-3779
CTO@hmc.psu.edu

Geisinger Medical Oncology-Lewisburg
Lewisburg, Pennsylvania 17837
Contact:
Site Public Contact
570-374-8555
HemonCCTrials@geisinger.edu

Allegheny General Hospital
Pittsburgh, Pennsylvania 15212
Contact:
Site Public Contact
877-284-2000

West Penn Hospital
Pittsburgh, Pennsylvania 15224
Contact:
Site Public Contact
412-578-5000

Geisinger Wyoming Valley/Henry Cancer Center
Wilkes-Barre, Pennsylvania 18711
Contact:
Site Public Contact
570-271-5251
HemonCCTrials@geisinger.edu

Sanford Cancer Center Oncology Clinic
Sioux Falls, South Dakota 57104
Contact:
Site Public Contact
605-312-3320
OncologyClinicTrialsSF@sanfordhealth.org

Sanford USD Medical Center - Sioux Falls
Sioux Falls, South Dakota 57117-5134
Contact:
Site Public Contact
605-312-3320
OncologyClinicalTrialsSF@SanfordHealth.org

Baptist Memorial Hospital and Cancer Center-Memphis
Memphis, Tennessee 38120
Contact:
Site Public Contact
901-226-1366
BCCclintrials@bmhcc.org

Vanderbilt University/Ingram Cancer Center
Nashville, Tennessee 37232
Contact:
Site Public Contact
800-811-8480

Huntsman Cancer Institute/University of Utah
Salt Lake City, Utah 84112
Contact:
Site Public Contact
888-424-2100
cancerinfo@hci.utah.edu

Bon Secours Memorial Regional Medical Center
Mechanicsville, Virginia 23116
Contact:
Site Public Contact
804-893-8978
anne_carmellat@bshsi.org

Bon Secours Saint Francis Medical Center
Midlothian, Virginia 23114
Contact:
Site Public Contact
804-893-8978
anne_carmellat@bshsi.org

Bon Secours Saint Mary's Hospital
Richmond, Virginia 23226
Contact:
Site Public Contact
804-893-8978
anne_carmellat@bshsi.org

Bon Secours Cancer Institute at Reynolds Crossing
Richmond, Virginia 23230
Contact:
Site Public Contact
804-893-8978
Anne_caramella@bshsi.org

Valley Medical Center
Renton, Washington 98055
Contact:
Site Public Contact
425-228-3440
research@valleymed.org

Edwards Comprehensive Cancer Center
Huntington, West Virginia 25701
Contact:
Site Public Contact
304-399-6566
Christina.Cole@chhi.org

Langlade Hospital and Cancer Center
Antigo, Wisconsin 54409
Contact:
Site Public Contact
715-623-9869
Juli.Alford@aspirus.org

Ascension Saint Elizabeth Hospital
Appleton, Wisconsin 54915
Contact:
Site Public Contact
AWRI.inquiry@ascension.org

Ascension Southeast Wisconsin Hospital - Elmbrook Campus
Brookfield, Wisconsin 53045
Contact:
Site Public Contact
AWRI.Inquiry@Ascension.org

Ascension Calumet Hospital
Chilton, Wisconsin 53014
Contact:
Site Public Contact
AWRI.inquiry@ascension.org

Ascension Southeast Wisconsin Hospital - Franklin
Franklin, Wisconsin 53132
Contact:
Site Public Contact
AWRI.Inquiry@Ascension.org

Ascension Columbia Saint Mary's Hospital Ozaukee
Mequon, Wisconsin 53097
Contact:
Site Public Contact
AWRI.Inquiry@Ascension.org

Ascension Southeast Wisconsin Hospital - Saint Joseph Campus
Milwaukee, Wisconsin 53210
Contact:
Site Public Contact
AWRI.Inquiry@Ascension.org

Ascension Columbia Saint Mary's Hospital - Milwaukee
Milwaukee, Wisconsin 53211
Contact:
Site Public Contact
AWRI.Inquiry@Ascension.org

Medical College of Wisconsin
Milwaukee, Wisconsin 53226
Contact:
Site Public Contact
414-805-3666

Ascension Mercy Hospital
Oshkosh, Wisconsin 54904
Contact:
Site Public Contact
AWRI.inquiry@ascension.org

Ascension All Saints Hospital
Racine, Wisconsin 53405
Contact:
Site Public Contact
AWRI.Inquiry@Ascension.org

Aspirus Cancer Care - James Beck Cancer Center
Rhinelander, Wisconsin 54501
Contact:
Site Public Contact
715-847-2353
Beth.Knetter@aspirus.org

Aspirus Cancer Care - Stevens Point
Stevens Point, Wisconsin 54481
Contact:
Site Public Contact
715-847-2353
Beth.Knetter@aspirus.org

Aspirus Regional Cancer Center
Wausau, Wisconsin 54401
Contact:
Site Public Contact
877-405-6866

Ascension Medical Group Southeast Wisconsin - Mayfair Road
Wauwatosa, Wisconsin 53226
Contact:
Site Public Contact
AWRI.Inquiry@Ascension.org

Aspirus Cancer Care - Wisconsin Rapids
Wisconsin Rapids, Wisconsin 54494
Contact:
Site Public Contact
715-422-7718

More Details

NCT ID
NCT05673148
Status
Recruiting
Sponsor
Alliance for Clinical Trials in Oncology

Study Contact

Eric D. Miller, MD, PhD
614-685-4922
eric.miller@osumc.edu

Detailed Description

PRIMARY OBJECTIVE: I. To evaluate and compare overall survival (OS) (measured from time of randomization) in patients with newly diagnosed oligometastatic colorectal cancer (oCRC) treated with total ablative therapy (TAT) in addition to standard of care (SOC) systemic therapy versus SOC systemic therapy. SECONDARY OBJECTIVES: I. To evaluate and compare event-free survival (EFS) (measured from time of randomization) between the two treatment arms. II. To assess the adverse events (AE) profile within each of the two treatment arms. III. To evaluate the time to local recurrence (TLR) (measured from completion of TAT) in patients with newly diagnosed oCRC treated with TAT + SOC systemic therapy. OUTLINE: Patients are randomized to 1 of 2 arms. ARM 1: Patients undergo TAT on study, consisting of SABR with or without surgical resection and/or microwave ablation. Patients also receive SOC chemotherapy on study. Patients also undergo computed tomography (CT) or magnetic resonance imaging (MRI) or positron emission tomography (PET)/CT scans throughout the trial. ARM 2: Patients receive SOC chemotherapy on study. Patients also undergo Patients also undergo CT or MRI or PET/CT scans throughout the trial.

For help using this page: trialstoday@researchmatch.org or call 855-514-7001

ResearchMatch is funded in part by the National Institutes of Health (NIH) Clinical and Translational Science Award (CTSA) program, led by the NIH’s National Center for Advancing Translational Sciences (NCATS), grants UL1TR000445 and 1U54RR032646-01, and grant U24TR001579 from NCATS and the National Library of Medicine. The content of this website is solely the responsibility of ResearchMatch and Vanderbilt University and does not necessarily represent the official views of the NIH, NCATS, or NLM.

Vanderbilt University Medical Center